Methotrexate and Adverse Events in CIRT Secondary Analysis
Although low-dose methotrexate has long been the first-line treatment for rheumatoid arthritis, the drug ’s safety is based on inconclusive and contradictory case reports and observational studies. The drug was associated with a small to modest increase in adverse events (AEs) among patients at high cardiovascular risk in a study in the Annals of Internal Medicine.
Source: JAMA - Category: General Medicine Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | General Medicine | Heart | Internal Medicine | Methotrexate | Rheumatoid Arthritis | Rheumatology | Study